KCNH2 and cancer: Here, we provided evidence for a novel therapeutic strategy for PDAC, based on a single chain bispecific antibody (scDb-hERG1-β1, which targets a cancer-specific antigen, the hERG1/β1 integrin complex), in combination with low, sub-optimal doses of Gemcitabine.